Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate

Kang, Yin-Feng; Sun, Cong; Zhuang, Zhen; Yuan, Run-Yu; Zheng, Qing-Bing; Li, Jiang-Ping; Zhou, Ping-Ping; Chen, Xin-Chun; Zhang, Xiao; Yu, Xiao-Hui; Kong, Xiang-Wei; Zhu, Qian-Ying; Xu, Miao; Zhong, Nan-Shan; Zeng, Yi-Xin; Feng, Guo-Kai; Ke, Chang-Wen; Zhao, Jin-Cun; Zeng, Mu-Sheng

The ongoing of coronavirus disease 2019 (COVID-19) pandemic caused by novel SARS-CoV-2 coronavirus, resulting in economic losses and seriously threating the human health in worldwide, highlighting the urgent need of a stabilized, easily produced and effective preventive vaccine. The SARS-COV-2 spike protein receptor binding region (RBD) plays an important role in the process of viral binding receptor angiotensin-converting enzyme 2 (ACE2) and membrane fusion, making it an ideal target for vaccine development. In this study, we designed three different RBD-conjugated nanoparticles vaccine candidates, RBD-Ferritin (24-mer), RBD-mi3 (60-mer) and RBD-I53-50 (120-mer), with the application of covalent bond linking by SpyTag-SpyCatcher system. It was demonstrated that the neutralizing capability of sera from mice immunized with three RBD-conjugated nanoparticles adjuvanted with AddaVax or Sigma Systerm Adjuvant (SAS) after each immunization was ~8-to 120-fold greater than monomeric RBD group in SARS-CoV-2 pseudovirus and authentic virus neutralization assay. Most importantly, sera from RBD-conjugated NPs groups more efficiently blocked the binding of RBD to ACE2 or neutralizing antibody in vitro, a further proof of promising immunization effect. Besides, high physical stability and flexibility in assembly consolidated the benefit for rapid scale-up production of vaccine. These results supported that our designed SARS-CoV-2 RBD-conjugated nanoparticle was competitive vaccine candidate and the carrier nanoparticles could be adopted as universal platform for future vaccine development.